Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges: 2023-2024

Historic Amortization of Deferred Charges for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $2.1 million.

  • Inhibrx Biosciences' Amortization of Deferred Charges was N/A to $638,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 57.85% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Amortization of Deferred Charges stood at $2.1 million for FY2024, which was down 57.85% from $4.9 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Amortization of Deferred Charges ranged from a high of $4.9 million in FY2023 and a low of $2.1 million during FY2024.
  • For the 2-year period, Inhibrx Biosciences' Amortization of Deferred Charges averaged around $3.5 million, with its median value being $3.5 million (2023).
  • Data for Inhibrx Biosciences' Amortization of Deferred Charges shows a maximum YoY plummeted of 57.85% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Amortization of Deferred Charges (Yearly) stood at $4.9 million in 2023, then slumped by 57.85% to $2.1 million in 2024.